Drug-induced Liver Injury
Conditions
Interventions
The treatment group 1:Protect liver treatment+glucocorticoid
The control group1:Protect liver treatment
The treatment group 2:Protect liver treatment+glucocorticoid
The control group2:Protect liver treatment
Sponsors
Beijing Beijing You'an Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Cholestasis type of severe drug-induced liver injury 1) Aged 18-70 years, gender not limited; 2) Criteria for diagnosis of cholestasis in drug-induced liver injury (2015 guidelines for drug-induced liver injury); 3) Total bilirubin 10*ULN above or >1mg/ day; 4) Sign the informed consent. Severe drug-induced liver injury with a tendency to liver failure 1) Aged 18-70 years, gender not limited; 2) Criteria for diagnosis of hepatocyte injury following drug-induced liver injury (2015 guidelines for drug-induced liver injury); 3) Total bilirubin 10*ULN above or rise >1mg/ day, 3-5 days PTA progressive decline more than 10%, or less than 60%, after vitamin K treatment ineffective; 4) Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Glucocorticoid therapy for contraindications; 2) Other basic liver diseases (except fatty liver) : such as hepatitis b and c virus infection, cirrhosis, etc.; 3) Acute and subacute liver failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Days of total bilirubin decrease > 50%;case fatality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function; | — |
Countries
China
Contacts
Public ContactZuopeng Fan
Beijing Beijing You'an Hospital Capital Medical University
Outcome results
None listed